Results 101 to 110 of about 11,895 (194)
ABSTRACT Statins, widely prescribed for cardiovascular prevention, have emerged as potential disease‐modifying agents in neurodegenerative disorders due to their pleiotropic effects on cholesterol metabolism, neuroinflammation, oxidative stress, and protein aggregation.
Luigi Maria Chiatto +7 more
wiley +1 more source
CTSL activates Notch1/RBPJ in a ligand‐independent fashion, inducing CUX1/p16INK4a‐dependent endothelial senescence associated with atherosclerosis. ABSTRACT Our post‐GWAS functional analysis revealed that cathepsin L (CTSL) is an upstream regulator of CUX1, and it induces p16INK4a‐dependent and atherosclerosis‐associated senescence by indirectly ...
Yuwei Wu +13 more
wiley +1 more source
<i>NOTCH2</i> gene mutation and gamma-secretase inhibitor in mediating the malignancy of ovarian cancer. [PDF]
Wang W +5 more
europepmc +1 more source
GGAs: Regulation of Multiple Sorting Pathways and Potential Association With Human Diseases
ABSTRACT Golgi‐localized gamma‐ear‐containing Arf‐binding proteins (GGAs) are a family of monomeric clathrin adaptors that function in intracellular vesicle trafficking. The three GGA family members—GGA1, GGA2 and GGA3—were first identified as sorting adaptors almost simultaneously by independent research groups in 2000. It is now well established that
Qinqin Wang +5 more
wiley +1 more source
Brain cholesterol homeostasis is tightly regulated and largely independent of peripheral cholesterol. This review proposes a unifying framework in which aging, sex, and related biological stressors, including hypercholesterolemia, neurodegeneration, inflammation, and oxidative stress, converge to disrupt cholesterol homeostasis in the brain ...
Myuri Ruthirakuhan +2 more
wiley +1 more source
Hidradenitis suppurativa: haploinsufficiency of gamma-secretase components does not affect gamma-secretase enzyme activityin vitro [PDF]
Pink, A. E. +9 more
openaire +5 more sources
Neurotrophin receptοrs, gamma-secretase inhibitors, and neurodegeneration of basal forebrain cholinergic neurons. [PDF]
Vilar M.
europepmc +1 more source
Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal, i.e. slowing of Alzheimer’s disease (AD) progression.
Bart De Strooper, Eric Karran
doaj +1 more source
High throughput and targeted screens for prepilin peptidase inhibitors do not identify common inhibitors of eukaryotic gamma-secretase. [PDF]
Singh PK, Donnenberg MS.
europepmc +1 more source

